SCHEMBL4214280

SCHEMBL4214280

O=C(c1ccc(F)cc1)c1ccc(Br)cc1F

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DGAT1 O75907 1/20 0.58
CES2 O00748 2/20 0.46
CES1 P23141 2/20 0.46
KMT2A Q03164 3/20 0.45
NPC1 O15118 2/20 0.45
ALDH1A1 P00352 2/20 0.45
LMNA P02545 2/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
GAA P10253 1/20 0.45
RAB9A P51151 1/20 0.45
MAPT P10636 4/20 0.45
POLB P06746 1/20 0.45
AKR1C3 P42330 1/20 0.43
LTA4H P09960 1/20 0.43
LSS P48449 2/20 0.42
MAPK1 P28482 1/20 0.41
HTT P42858 1/20 0.41
FLT1 P17948 1/20 0.41
FLT4 P35916 1/20 0.41
KDR P35968 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5307521 0.89 CES2 (0.55) DGAT1CES2CES1KMT2ANPC1
SCHEMBL3467995 0.88 DGAT1 (0.56) DGAT1KMT2ANPC1ALDH1A1LMNA
SCHEMBL3025807 0.86 KMT2A (0.61) DGAT1KMT2ANPC1ALDH1A1LMNA
SCHEMBL1128877 0.86 MAPT (0.62) DGAT1KMT2ANPC1ALDH1A1LMNA
SCHEMBL8609990 0.85 CES2 (0.63) CES2CES1KMT2AALDH1A1LMNA
SCHEMBL29880739 0.85 CES2 (0.63) CES2CES1KMT2AALDH1A1LMNA
SCHEMBL4464312 0.85 DGAT1 (0.70) DGAT1CES2CES1KMT2ANPC1
SCHEMBL2989871 0.84 HPGD (0.47) DGAT1CES2CES1KMT2ANPC1
SCHEMBL5235450 0.83 AKR1C3 (0.57) DGAT1ALDH1A1MAPTPOLBAKR1C3
SCHEMBL5235158 0.83 AKR1C3 (0.57) DGAT1ALDH1A1MAPTPOLBAKR1C3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12540130-B2 Substituted pyrrolidine amides IV GRUENENTHAL GMBH (DE) 2026-02-03 US disclosed
EP-3986885-B1 SUBSTITUTED PYRROLIDINE AMIDES IV GRUENENTHAL GMBH (DE) 2023-05-03 EP disclosed
EP-3986885-B1 SUBSTITUTED PYRROLIDINE AMIDES IV GRUENENTHAL GMBH (DE) 2023-05-03 EP disclosed
EP-3986885-A1 SUBSTITUTED PYRROLIDINE AMIDES IV Grünenthal GmbH (DE) 2022-04-27 EP disclosed
US-20220106295-A1 SUBSTITUTED PYRROLIDINE AMIDES IV GRUENENTHAL GMBH (DE) 2022-04-07 US disclosed
WO-2020254551-A1 SUBSTITUTED PYRROLIDINE AMIDES IV Grünenthal GmbH (DE) 2020-12-24 WO disclosed
WO-2020254551-A1 SUBSTITUTED PYRROLIDINE AMIDES IV Grünenthal GmbH (DE) 2020-12-24 WO disclosed
EP-3138842-B1 POLYFLUORINATED COMPOUNDS ACTING AS BRUTON'S TYROSINE KINASE INHIBITORS ZHEJIANG DTRM BIOPHARMA CO LTD (CN) 2020-12-09 EP disclosed
EP-3138842-B1 POLYFLUORINATED COMPOUNDS ACTING AS BRUTON'S TYROSINE KINASE INHIBITORS ZHEJIANG DTRM BIOPHARMA CO LTD (CN) 2020-12-09 EP disclosed
US-10300066-B2 Polyfluorinated compounds acting as bruton tyrosine kinase inhibitors Zhejiang DTRM Biopharma Co. Ltd. (CN) 2019-05-28 US disclosed
US-20160200730-A1 POLYFLUORINATED COMPOUNDS ACTING AS BRUTON TYROSINE KINASE INHIBITORS Zhejiang DTRM Biopharma Co. Ltd. (CN) 2016-07-14 US disclosed
US-20160200730-A1 POLYFLUORINATED COMPOUNDS ACTING AS BRUTON TYROSINE KINASE INHIBITORS Zhejiang DTRM Biopharma Co. Ltd. (CN) 2016-07-14 US disclosed
US-20160200730-A1 POLYFLUORINATED COMPOUNDS ACTING AS BRUTON TYROSINE KINASE INHIBITORS Zhejiang DTRM Biopharma Co. Ltd. (CN) 2016-07-14 US disclosed
WO-2015165279-A1 POLYFLUORINATED COMPOUNDS ACTING AS BRUTON'S TYROSINE KINASE INHIBITORS 浙江导明医药科技有限公司 2015-11-05 WO disclosed
US-20090023725-A1 Fused Heteroaryl Derivatives for Use as P38 Kinase Inhibitors SMITHKLINE BEECHAM CORPORATION 2009-01-22 US disclosed
US-20090023725-A1 Fused Heteroaryl Derivatives for Use as P38 Kinase Inhibitors SMITHKLINE BEECHAM CORPORATION 2009-01-22 US disclosed
US-20090023725-A1 Fused Heteroaryl Derivatives for Use as P38 Kinase Inhibitors SMITHKLINE BEECHAM CORPORATION 2009-01-22 US disclosed
EP-1708996-B1 FUSED HETEROYRAL DERIVATIVES FOR USE AS P38 KINASE INHIBITORS SMITHKLINE BEECHAM CORP (US) 2008-08-27 EP disclosed
EP-1708996-A1 FUSED HETEROYRAL DERIVATIVES FOR USE AS P38 KINASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2006-10-11 EP disclosed
WO-2005073189-A1 FUSED HETEROYRAL DERIVATIVES FOR USE AS P38 KINASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2005-08-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160200730-A1 POLYFLUORINATED COMPOUNDS ACTING AS BRUTON TYROSINE KINASE INHIBITORS BTK, LCK, LYN DGAT1 3157/4885CES2 2531/4885CES1 2235/4885
US-12540130-B2 Substituted pyrrolidine amides IV NR3C1, NR3C2, CRHR1 DGAT1 1942/4885CES2 1134/4885CES1 330/4885
US-20090023725-A1 Fused Heteroaryl Derivatives for Use as P38 Kinase Inhibitors MAPK1, MAPKAPK2, MAPK7 DGAT1 3304/4885CES2 3964/4885CES1 2339/4885
US-20220106295-A1 SUBSTITUTED PYRROLIDINE AMIDES IV NR3C1, NR3C2, MC2R DGAT1 3638/4885CES2 2185/4885CES1 1207/4885
US-10300066-B2 Polyfluorinated compounds acting as bruton tyrosine kinase inhibitors BTK, LCK, LYN DGAT1 3157/4885CES2 2531/4885CES1 2235/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.